TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00640263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r)
Description: Oral liquid formulation lopinavir/ritonavir(80 mg lopinavir + 20 mg ritonavir/mL); Dosing : 40/10mg twice daily if infant weight is between 2 to 4 kg and 80/20mg twice daily if infant weight is above 4kg The lopinavir/ritonavir will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine (3TC)
Description: Oral liquid solution lamivudine(10 mg/mL). Dosing : 7,5 mg twice daily if if infant weight is between 2 to 4 kg ; 25 mg twice daily if infant weight is between 4 to 8 kg ; 50 mg twice daily if infant weight is above 8kg.~The lamivudine will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight.
Study: NCT02590913

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fructose
Description: 75g fructose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fructose
Description: 75g fructose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose
Description: 75g glucose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose
Description: 75g glucose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
Study: NCT04479254

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral Nutrients ( Nutren Optimum, Nutren Diabetes, Novasource Renal ), Parenteral Nutrient ( Smofkabiven)
Description: Enteral nutrition feeding formula is used in powder form and will be reconstituted by attending nurses, Continuous feeding is commonly used which will be prescribed by the attending clinicians, Energy and protein intake from EN will be estimated by multiplying the volume of feed given to energy (kcal) and protein (g) in 1 ml of standard dilution, and for Standard PN product, energy and protein intake will also be calculated based on the volume infused.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Nutrients ( Nutren Optimum, Nutren Diabetes, Novasource Renal ), Parenteral Nutrient ( Smofkabiven)
Description: Enteral nutrition feeding formula is used in powder form and will be reconstituted by attending nurses, Continuous feeding is commonly used which will be prescribed by the attending clinicians, Energy and protein intake from EN will be estimated by multiplying the volume of feed given to energy (kcal) and protein (g) in 1 ml of standard dilution, and for Standard PN product, energy and protein intake will also be calculated based on the volume infused.
Study: NCT00780663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quarfloxin
Description: IV Quarfloxin 240 mg/m2 daily x5 days every 21 days
Study: NCT00940992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DER 45 EV
Description: Topical application to face for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DER 45 EV
Description: Topical application to face for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical application to face for 12 weeks
Study: NCT04401917

Intervention type: DRUG
Group type: OTHER
Intervention: [18F]NOS
Description: Participants will undergo approximately 60 minutes of dynamic whole-body scanning, including the brain, starting at approximately the time of injection of \[18F\]NOS. PET/CT imaging sessions will include an injection of ≤ 6.5 mCi (approximate range for most studies is anticipated to be 3.5-6.5 mCi) of \[18F\]NOS.

Intervention type: DRUG
Group type: OTHER
Intervention: [18F]NOS
Description: Participants will undergo approximately 60 minutes of dynamic whole-body scanning, including the brain, starting at approximately the time of injection of \[18F\]NOS. PET/CT imaging sessions will include an injection of ≤ 6.5 mCi (approximate range for most studies is anticipated to be 3.5-6.5 mCi) of \[18F\]NOS.

Intervention type: DRUG
Group type: OTHER
Intervention: [18F]NOS
Description: Participants will undergo approximately 60 minutes of dynamic whole-body scanning, including the brain, starting at approximately the time of injection of \[18F\]NOS. PET/CT imaging sessions will include an injection of ≤ 6.5 mCi (approximate range for most studies is anticipated to be 3.5-6.5 mCi) of \[18F\]NOS.

Intervention type: DRUG
Group type: OTHER
Intervention: [18F]NOS
Description: Participants will undergo approximately 60 minutes of dynamic whole-body scanning, including the brain, starting at approximately the time of injection of \[18F\]NOS. PET/CT imaging sessions will include an injection of ≤ 6.5 mCi (approximate range for most studies is anticipated to be 3.5-6.5 mCi) of \[18F\]NOS.
Study: NCT03245541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be given 750 mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q14 days beginning D1. Four doses of durvalumab will be administered on the Q14 day schedule. Subsequently Durvalumab will continue as maintenance 1500mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q28 days up to 1 year or until progression (11 doses), unacceptable toxicity or other reason. If a patient undergoes resection, they will resume durvalumab once appropriately healed from surgery (approximately 4-8 weeks) at discretion of treating medical oncologist.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiotherapy (SABR)
Description: SABR delivered as 6.6 Gy/fraction x 5 fractions given within two weeks will be administered weekdays and will begin D8.
Study: NCT00256243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2 IV, bolus once every 14 days x 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV once every 14 days x 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 IV over 1 hour once weekly for 9-12 doses beginning two weeks after completion of last AC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the concentration curve (AUC) 2 IV once weekly for 9-12 doses beginning two weeks after completion of last AC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 μg/mL IV on day 5-14 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
Study: NCT03706170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EEG recording in response to different types of stimuli
Description: In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
Study: NCT03033446

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Y-90 Radioembolization
Description: Dose of Yttrium-90 is determined based on BSA, size of liver tumor, and dose modifications required for percent lung shunting between 10-20% on the Tc-99MMA scan
Study: NCT01923376

Intervention type: DRUG
Group type: OTHER
Intervention: Lactulose
Description: If randomized to this group, subjects will receive 10 - 30 grams of lactulose per standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol 3350
Description: If subject is randomized to this group, one time dose of one gallon polyethylene glycol 3350 will be given at the time of enrollment
Study: NCT02128035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: With Lead Shield
Description: A pelvic lead shield will be draped on patient from umbilicus to knees.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures.
Study: NCT01881074

Intervention type: DRUG
Intervention: Triclosan containing toothpaste
Description: Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the triclosan containing toothpaste provided to them. Additional tubes of triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.

Intervention type: DRUG
Intervention: Non-triclosan containing toothpaste
Description: Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the non-triclosan containing toothpaste (i.e. placebo) provided to them. Additional tubes of non-triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
Study: NCT00635375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED fiberoptic blanket phototherapy (BiliSoft blue LED fiberoptic blanket phototherapy)
Description: 35-50 mW/cm2/nm
Study: NCT03296982

Intervention type: OTHER
Intervention: Blood drawn by direct venipuncture
Description: Subjects will have blood sampled (12 mL/sample) a total of 8 times by direct venipuncture. Samples will be spiked with predetermined concentrations of anticoagulants, or saline sham.

Intervention type: DRUG
Intervention: edoxaban

Intervention type: DRUG
Intervention: Enoxaparin

Intervention type: DRUG
Intervention: Saline sham
Study: NCT02610361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-283
Description: In the dose escalation part(phase 1a): the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In dose expansion phase(Phase 1b): Patients will be assigned to different groups based on their tumor types
Study: NCT03033446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks
Study: NCT02427477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: Subjects will wear the contact lenses in both eyes for seven days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A
Description: Subjects will wear the contact lenses in both eyes for seven days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: delefilcon A
Description: Subjects will wear the contact lenses in both eyes for seven days
Study: NCT00986258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Prolonged Release
Description: Participants started with 50 mg, 100 mg or 150 mg tapentadol prolonged release (PR) twice daily. Opioid rotation to tapentadol was scheduled as follows:~* if less than 100 mg morphine equivalent start with 50 mg tapentadol PR;~* if on 101 to 160 mg morphine equivalent daily dose start with 100 mg tapentadol PR;~* if above 161 mg morphine equivalent daily dose start with 150 mg tapentadol PR.~Tapentadol doses were adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis). After 5 weeks, the doses of tapentadol PR were kept stable (start of Maintenance phase). The tapentadol PR formulation was administered for up to 12 weeks. Tapentadol immediate release 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol immediate release any more when a daily dose of 500 mg tapentadol PR was reached.
Study: NCT01971489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03951857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise with a gym stick
Description: Exercise intervention: The resistance exercise intervention is performed with a gym stick for 3 times a week for 12 weeks. Exercise load is gradually increased by the number of times the band is wound and the speed of motion by dividing into three stages in 1-4 weeks (1st stage), 5-8 weeks (2nd stage) and 9-12 weeks (3rd stage).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise with a gym stick
Description: Exercise intervention: The resistance exercise intervention is performed with a gym stick for 3 times a week for 12 weeks. Exercise load is gradually increased by the number of times the band is wound and the speed of motion by dividing into three stages in 1-4 weeks (1st stage), 5-8 weeks (2nd stage) and 9-12 weeks (3rd stage).
Study: NCT00579072

Intervention type: BEHAVIORAL
Intervention: Questionaires
Description: We will use a 6-month longitudinal design to assess the short-term cognitive effects of androgen ablation therapy. We will collect 6-month longitudinal data on 170 men with prostate cancer. All 170 men will be hormone naïve at the start of this study (Hormone Naïve Group). These 170 men will consist of two subgroups. The first subgroup will comprise 70 men with prostate cancer age 65 and older scheduled to start androgen ablation therapy. Their cognitive functioning will be assessed prior to starting androgen ablation therapy or within 21 days after initiation, (i.e. baseline) and then 6 months later (Androgen Ablation Subgroup).The second subgroup will serve as a control group, and consist of 100 men with prostate cancer age 65 and older who are at least 1-year post definitive localized treatment with no evidence of disease and no plan to start androgen ablation therapy (No Androgen Ablation Subgroup).

Intervention type: BEHAVIORAL
Intervention: Questionaires
Description: To supplement the pilot data collected in Aim 1, Aim 2 we will utilize a group comparison design to assess the long-term cognitive effects of androgen ablation therapy. We will collect data on the cognitive functioning of 110 men with prostate cancer age 65 and older who have been on continuous androgen ablation therapy for 1-3 years (2-Year Androgen Ablation Group). These men will complete the study battery once (i.e., the neuropsychological battery, psychosocial questionnaires, and a functional status battery). We will compare the cognitive functioning of these 110 men in the 2-Year Androgen Ablation Group to the 170 men with prostate cancer who are hormone naïve (Hormone Naïve Group).
Study: NCT02752529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus（FK506）

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus（FK506）
Study: NCT01597557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: 2 grams intravenous drip over 30 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 50 ml intravenous drip over 30 minutes
Study: NCT00579072

Intervention type: DEVICE
Intervention: fMRI scan (optional)
Description: Main study participants will be offered to complete an optional fMRI. Fifteen participants from the No Androgen Ablation Subgroup and 15 participants from the Comparison Androgen Ablation Subgroup or Longitudinal Androgen Ablation Subgroup will be recruited for this portion of the study. The fMRI will be scheduled either the same day as the neurocognitive assessment or within eight weeks of the neurocognitive testing. The fMRI will be performed only once at baseline for the Comparison Androgen Ablation Subgroup. The fMRI will be performed at the follow-up time point for the Longitudinal Androgen Ablation Subgroup. The fMRI will be performed at baseline for the No Androgen Ablation Subgroup; if the fMRI can not be completed at baseline (due to participant schedule conflict, lack of fMRI availability, staff schedule conflict, etc.), then the scan will be conducted at the follow-up time point if possible.

Intervention type: DEVICE
Intervention: fMRI scan (optional)
Description: Main study participants will be offered to complete an optional fMRI. Fifteen participants from the No Androgen Ablation Subgroup and 15 participants from the Comparison Androgen Ablation Subgroup or Longitudinal Androgen Ablation Subgroup will be recruited for this portion of the study. The fMRI will be scheduled either the same day as the neurocognitive assessment or within eight weeks of the neurocognitive testing. The fMRI will be performed only once at baseline for the Comparison Androgen Ablation Subgroup. The fMRI will be performed at the follow-up time point for the Longitudinal Androgen Ablation Subgroup. The fMRI will be performed at baseline for the No Androgen Ablation Subgroup; if the fMRI can not be completed at baseline (due to participant schedule conflict, lack of fMRI availability, staff schedule conflict, etc.), then the scan will be conducted at the follow-up time point if possible.
Study: NCT03221452

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Memory, Attention, and Problem Solving Skills for Diabetes
Description: Classes will include: (1) information on diabetes self-management including glucose self-monitoring and medication management; (2) assessment of cognitive problems; (3) resources and barriers to self-management; and (4) lifestyle changes to maximize cognitive health. Participants will also practice those skills with online computer games.
Study: NCT03267498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.
Study: NCT00256243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: AUC 2 IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
Study: NCT04527562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Participants in this group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
Study: NCT03709446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Single agent leflunomide
Study: NCT00635375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metal halide phototherapy (Spot PT metal halide phototherapy)
Description: 29.3-57.6 mW/cm2/nm
Study: NCT04527562

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this group will be given a starting dose of 2 tablets of Placebo, single or 12 hourly divided dose. After that, they will take one placebo tablet daily for 13 days.Placebo tablet will be identical with the Colchicine tablet. If patients develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
Study: NCT03302416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Study: NCT03267498

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday
Study: NCT03302416

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]NOP-1A
Study: NCT01293032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy
Description: Undergo neoadjuvant therapy
Study: NCT04452591

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cretostimogene Grenadenorepvec
Description: Engineered Oncolytic Adenovirus
Study: NCT03036332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Description: Carried out 3 times per week for 16 weeks
Study: NCT01318473

Intervention type: DEVICE
Group type: OTHER
Intervention: ActiSight™ Needle Guidance System
Description: ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
Study: NCT00635375

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED bank phototherapy (Natus neoBlue LED bank phototherapy)
Description: 12-35 mW/cm2/nm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metal halide plus LED fiberoptic blanket phototherapy (BiliSoft and Spot PT)
Description: 29.3-57.6 mW/cm2/nm and 35-50 mW/cm2/nm
Study: NCT02898129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung function test
Description: Basic lung function test performed with a micro-spirometer, without broncho dilatator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung function test
Description: Basic lung function test performed with a micro-spirometer, without broncho dilatator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung function test
Description: Basic lung function test performed with a micro-spirometer, without broncho dilatator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung function test
Description: Basic lung function test performed with a micro-spirometer, without broncho dilatator